🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

Showing page 158 of 857 · Phase 3 first, then by program name

  1. Reslizumab

    Teva Generics B.V

    Eosinophilic Asthma

    phase 3 small molecule terminated

    1 trial

  2. Reslizumab

    Teva Pharma GmbH

    Eosinophilic Asthma

    phase 3 small molecule completed

    5 trials

  3. Reslizumab

    Teva Pharma GmbH

    Severe Persistent Asthma

    phase 3 mab completed

    1 trial

  4. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    NASH

    phase 3 small molecule active

    1 trial

  5. Resmetirom

    Madrigal Pharmaceuticals EU Limited

    Non-Alcoholic Fatty Liver Disease

    phase 3 small molecule active

    1 trial

  6. Retatrutide, Tirzepatide, Retatrutide, Tirzepatide, Tirzepatide, Tirzepatide, Retatrutide, Retatrutide, Retatrutide, Tirzepatide, Tirzepatide

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  7. Retifanlimab (INCMGA00012), CARBOPLATINE ACCORD 10 mg/ml, solution pour perfusion, Bendatax 6 mg/ ml, Placebo liquid (not containing the active substance, otherwise identical to INCMGA0012)

    Incyte

    Squamous Carcinoma of the Anal Canal

    phase 3 small molecule active

    1 trial

  8. Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 25 mg solution for injection in pre-filled syringe, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Enbrel 10 mg powder and solvent for solution for injection for paediatric use, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempita, Reumaflex 50 mg/ml soluzione iniettabile, siringa preriempi

    The George Institute

    juvenile idiopathic arthritis

    phase 3 small molecule active

    1 trial

  9. Revatio 0.8 mg/ml solution for injection

    Pari Pharma GmbH

    Hypoxic ischemic encephalopathy

    phase 3 small molecule active

    1 trial

  10. Revefenacin

    Theravance Biopharma Ireland Umited

    Chronic Obstructive Pulmonary Disease, COPD

    phase 3 small molecule completed

    2 trials

  11. Revlimid 10 mg hard capsules, DIPHENHYDRAMINE , Revlimid 20 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 5 mg hard capsules, Revlimid 10 mg hard capsules, Isatuximab, Revlimid 25 mg hard capsules, Zelvina 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Zelvina 10 mg hard capsules, PARACETAMOL , Zelvina 20 mg hard capsules, MONTELUKAST , METHYLPREDNISOLONE , Revlimid 5 mg hard capsules, Revlimid 20 mg hard capsules, Zelvina 15 mg hard capsules, Isa

    Sanofi-aventis Healthcare Pty Ltd

    Plasma cell myeloma

    phase 3 small molecule active

    1 trial

  12. Revlimid 10 mg hard capsules, Zelvina 10 mg hard capsules, MINJUVI 200 mg powder for concentrate for solution for infusion, Zelvina 15 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 5 mg hard capsules, Revlimid 20 mg hard capsules, 0.9% saline solution for infusion. The placebo (250 mL infusion container with 0.9% (w/v) sodium chloride for injection) is being sourced locally from commercial market and delivered to an unblinded pharmacy., Revlimid 15 mg hard capsules, Truxima 100 mg concentrate for s

    Incyte

    follicular lymphoma (FL) and marginal zone lymphoma (MZL)

    phase 3 small molecule active

    1 trial

  13. Revlimid 2.5 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 25 mg hard capsules, SOLDESAM 0,2% gocce orali, soluzione, Kyprolis 60 mg powder for solution for infusion

    Fondazione Telethon ETS

    PATIENTS WITH NEW DIAGNOSIS MULTIPLE MYELOMA WITH AGE >= 65 YEARS OR NOT ELIGIBLE TO ASCT

    phase 3 small molecule active

    1 trial

  14. Revlimid 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, VELCADE 3.5 mg powder for solution for injection, DEXAMETHASONE , Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 15 mg hard capsules, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Revlimid 10 mg hard capsules, DARZALEX 1800 mg solution for injection

    Janssen-Cilag International N.V.

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  15. Revlimid 25 mg hard capsules, Revlimid 5 mg hard capsules, Zelvina 15 mg hard capsules, Dexamethasone 3.3 mg/ml solution for injection, Zelvina 25 mg hard capsules, Revlimid 20 mg hard capsules, Revlimid 5 mg hard capsules, Isatuximab, Zelvina 10 mg hard capsules, Revlimid 10 mg hard capsules, DexaGalen® 8 mg injekt Injektionslösung, Revlimid 15 mg hard capsules, Revlimid 10 mg hard capsules, Zelvina 20 mg hard capsules, Dexamethason 4 mg JENAPHARM®, Zelvina 5 mg hard capsules, Revlimid 25 mg hard capsules,

    Sanofi-aventis Healthcare Pty Ltd

    Cancer

    phase 3 small molecule active

    1 trial

  16. Revumenib

    United Therapeutics Europe Ltd

    Acute Myeloid Leukemia, Adult

    phase 3 small molecule active

    1 trial

  17. Revumenib

    Syndax Pharmaceuticals

    Acute Myeloid Leukemias

    phase 3 small molecule active

    1 trial

  18. Revumenib, Revumenib, Placebo for Revumenib tablets, CYTARABINE, IDARUBICIN HYDROCHLORIDE, DAUNORUBICIN HYDROCHLORIDE, Revumenib

    Syndax Pharmaceuticals

    Newly Diagnosed AML with an NPM1 mutation

    phase 3 small molecule active

    1 trial

  19. Revusiran (ALN-TTRSC)

    Alnylam Netherlands B.V.

    Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)

    phase 3 small molecule completed

    1 trial

  20. Ribavirin

    Vertex Pharmaceuticals (Australia) Pty.

    Genotype 1 Chronic Hepatitis C

    phase 3 small molecule completed

    1 trial

  21. Ribociclib

    Novartis Pharmaceuticals

    Breast Cancer

    phase 3 small molecule completed

    1 trial

  22. Ribociclib

    Novartis Pharmaceuticals

    Advanced, Metastatic Breast Cancer

    phase 3 small molecule completed

    1 trial

  23. Ridinilazole

    Summit Therapeutics

    Clostridioides Difficile Infection

    phase 3 small molecule completed

    2 trials

  24. Rifampicin

    Ultragenyx UK Limited

    Multiple System Atrophy

    phase 3 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources